君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

休市中 12-12 16:08:09

24.000

+0.500

+2.13%

最高24.360	最低23.220	成交量370.76万
今开23.600	昨收23.500	日振幅4.85%
总市值246.48亿	流通市值62.40亿	总股本10.27亿
成交额8,883万	换手率1.43%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":24,"timestamp":1765526889002,"preClose":23.5,"halted":0,"volume":3707600,"delay":0,"floatShares":260000000,"shares":1027000000,"eps":-1.4341353336653389,"marketStatus":"休市中","change":0.5,"latestTime":"12-12 16:08:09","open":23.6,"high":24.36,"low":23.22,"amount":88829643,"amplitude":0.048511,"askPrice":24.14,"askSize":279400,"bidPrice":24,"bidSize":42000,"shortable":3,"etf":0,"ttmEps":-1.057904270231574,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":23.5,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":1.4649681529067613,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":36.58,"timestamp":1765522800000,"preClose":36.31,"halted":0,"volume":7775600,"delay":0,"premium":"-40.53"}},"requestUrl":"/m/hq/s/01877/tweets","defaultTab":"tweets","newsList":[{"id":"2590050825","title":"每日卖空追踪 | 君实生物 12月12日卖空量成交5万股，卖空比例为1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590050825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590050825?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528223,"startTime":"0","endTime":"0","summary":"君实生物北京时间12月12日，涨2.13%，卖空量成交5万股，较上一交易日减少31.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165406a4446b50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165406a4446b50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","01877","BK1583"],"gpt_icon":0},{"id":"2591681561","title":"君实生物12月12日主力净流入464.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2591681561","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591681561?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:16","pubTimestamp":1765527362,"startTime":"0","endTime":"0","summary":"12月12日, 君实生物股价涨2.13%，报收24.00元，成交金额8883.0万元，换手率1.42%，振幅4.85%，量比1.46。君实生物今日主力资金净流入464.4万元，上一交易日主力净流出169.7万元。该股近5个交易日下跌2.38%，主力资金累计净流入540.1万元；近20日主力资金累计净流入1997.9万元，其中净流入天数为11日。该股主力净额占比0.08%，港股市场排名125/2691。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162859a4445eb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162859a4445eb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","159992","LU1951186391.HKD","LU0043850808.USD","LU2778985437.USD","HK0000165453.HKD","LU0181495838.USD","LU0516423091.SGD","LU0067412154.USD","LU2097828557.USD","LU0502904849.HKD","LU1226287529.USD","LU0359201612.USD","LU0634319403.HKD","LU1961090484.USD","01801","02142","LU0708995583.HKD","02616","LU0417516738.SGD","BK1161","01877","LU0359202008.SGD","09995","02269","LU1993786604.SGD","LU1969619763.USD","SG9999004220.SGD","01093","LU0540923850.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1588","LU1770034418.SGD","06160","LU0348766576.USD","01177","06185","LU2097828714.EUR","03329","09688","LU2097828631.EUR","LU0456827905.SGD","LU2242644610.SGD","09926","LU2328871848.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","06978","LU1242518931.SGD"],"gpt_icon":0},{"id":"2590796215","title":"君实生物前三季营收增超四成，女CEO邹建军为肿瘤学博士、去年领薪近九百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590796215","media":"瑞财社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590796215?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:15","pubTimestamp":1765448124,"startTime":"0","endTime":"0","summary":"报告显示，君实生物公司前三季度营业收入为18.06亿元，同比增长42.06%；归母净利润为-5.96亿元，同比增长35.72%；扣非归母净利润为-6.70亿元，同比增长28.73%；基本每股收益-0.60元。君实生物前三季度期间费用为21.07亿元，较上年同期增加1.88亿元；期间费用率为116.66%，较上年同期下降34.28个百分点。据东方财富网数据，君实生物总经理兼CEO邹建军2022-2024年分别领薪432.5万元、586.2万元和898.7万元，三年间涨薪超一倍。邹建军，女，1971年7月出生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211181944979c99cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211181944979c99cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877"],"gpt_icon":0},{"id":"2590568001","title":"创新药热潮与商业化红利共振 BD交易额破1200亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568001","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590568001?lang=zh_cn&edition=full","pubTime":"2025-12-11 08:42","pubTimestamp":1765413720,"startTime":"0","endTime":"0","summary":"跨国药企面临严峻的专利悬崖问题，中国创新药作为其管线补充的重要来源之一，在2025年迎来BD爆发元年，交易数据持续攀升。10月创新药BD交易仍然频繁，交易总额达200亿美元，截止10月底，2025年的BD累计交易总额已超过1200亿美元，同比增长190%，这表明BD交易已从偶发事件逐渐转变为行业常态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512110843099536967a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512110843099536967a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01801","BK1515","01877","06160","BK1583","06978"],"gpt_icon":0},{"id":"2590258535","title":"君实生物： JS207目前处于II期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2590258535","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590258535?lang=zh_cn&edition=full","pubTime":"2025-12-10 18:03","pubTimestamp":1765361035,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问公司目前是否有JS207（PD-1/VEGF双抗）与JS212（EGFR/HER3双抗ADC）联合临床实验在推进，或者有该联合方案的计划，如果有，能否介绍一下目前进展情况？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512103587782740.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587782740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1515","688180","01877","BK0239","BK1161"],"gpt_icon":0},{"id":"2590583171","title":"君实生物控股股东兼董事长熊俊已增持10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583171","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583171?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:51","pubTimestamp":1765360274,"startTime":"0","endTime":"0","summary":"12月10日，君实生物（688180/01877）发布公告，控股股东兼董事长熊俊自2025年4月12日起计划在12个月内增持公司股份，已通过集中竞价增持10万股A股，累计增持金额为384万元。2025年前三季度，君实生物实现收入18.06亿元，归母净利润-5.96亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587770478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","688180","01877","BK1161","BK1515","BK0239"],"gpt_icon":0},{"id":"2590563866","title":"每日卖空追踪 | 君实生物 12月10日卖空量成交3.14万股，卖空比例为2.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563866","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563866?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355425,"startTime":"0","endTime":"0","summary":"君实生物北京时间12月10日，跌0.17%，卖空量成交3.14万股，较上一交易日减少89.83%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016335295353ce4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016335295353ce4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1515","BK1161"],"gpt_icon":0},{"id":"2590065568","title":"君实生物12月10日遭主力抛售134.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590065568","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590065568?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:15","pubTimestamp":1765354547,"startTime":"0","endTime":"0","summary":"12月10日, 君实生物股价跌0.17%，报收23.50元，成交金额3578.8万元，换手率0.59%，振幅2.97%，量比0.66。君实生物今日主力资金净流出134.3万元，上一交易日主力净流出42.1万元。该股近5个交易日下跌0.76%，主力资金累计净流入391.3万元；近20日主力资金累计净流入1538.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016193295353538&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016193295353538&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1515","BK1161"],"gpt_icon":0},{"id":"2590367035","title":"【券商聚焦】交银国际：2025年医保+商保双目录落地 多元支付体系盘活创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367035?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:59","pubTimestamp":1765241994,"startTime":"0","endTime":"0","summary":"调整后的目录中，药品总数增至3,253种。新版目录将于2026年1月1日正式实施。该机构认为，更多新药进入目录有助于提升临床用药水平，及创新药行业整体研发回报率；商保资金的引入将为创新药支付带来重要增量资金，为多元化支付体系的建立奠定基础。百济有两款产品纳入商保创新药目录，信达、和黄各有一款纳入。同时重点关注首批商保目录的实际执行和支付情况、名单及定价的动态调整以及真实世界数据积累带来的长期发展机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971149","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU0708995583.HKD","06185","LU0456827905.SGD","LU0572944931.SGD","LU1969619763.USD","BK1191","LU2476274308.USD","BK1161","LU0417516902.SGD","LU2399975544.HKD","09926","IE00B0JY6N72.USD","LU0327786744.USD","LU1719994722.HKD","02142","LU0348767384.USD","01177","06978","LU1951186391.HKD","BK1610","LU0348783233.USD","09995","LU0326950275.SGD","BK1141","BK1588","LU0880133367.SGD","01801","LU1226288170.HKD","02269","01877","LU0348784397.USD","LU0516423091.SGD","IE00B543WZ88.USD","LU1770034418.SGD","LU2039709279.SGD","LU0348766576.USD","BK1147","06160","LU0181495838.USD","159992","LU1813983027.USD","03329","02616","09688","LU0140636845.USD","BK1574","BK1576","IE00BZ08YR35.GBP","01093"],"gpt_icon":0},{"id":"2589133259","title":"每日卖空追踪 | 君实生物 12月08日卖空量成交8.72万股，卖空比例为3.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589133259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589133259?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182624,"startTime":"0","endTime":"0","summary":"君实生物北京时间12月08日，涨0.85%，卖空量成交8.72万股，较上一交易日增加3.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081633319531090f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081633319531090f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2590395512","title":"君实生物12月08日获主力加仓421.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395512","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395512?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181754,"startTime":"0","endTime":"0","summary":"12月08日, 君实生物股价涨0.85%，报收23.76元，成交金额5493.7万元，换手率0.89%，振幅4.07%，量比1.16。君实生物今日主力资金净流入421.8万元，连续3日净流入，上一交易日主力净流入104.1万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为63.64%，平均涨幅为3.09%。该股近5个交易日下跌4.12%，主力资金累计净流入78.2万元；近20日主力资金累计净流入1964.1万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208162112a72aa6c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208162112a72aa6c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1515","01877"],"gpt_icon":0},{"id":"2589332307","title":"君实生物12月5日获融资买入1101.36万元，融资余额13.49亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589332307","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589332307?lang=zh_cn&edition=full","pubTime":"2025-12-08 13:05","pubTimestamp":1765170325,"startTime":"0","endTime":"0","summary":"两融数据显示，当日君实生物获融资买入额1101.36万元，融资偿还1471.71万元，融资净买入-370.35万元。截至12月5日，君实生物融资融券余额合计13.63亿元。融资方面，君实生物当日融资买入1101.36万元。融券方面，君实生物12月5日融券偿还3490.00股，融券卖出1.63万股，按当日收盘价计算，卖出金额58.68万元；融券余量38.16万股，融券余额1373.60万元，超过近一年90%分位水平，处于高位。截至9月30日，君实生物股东户数3.59万，较上期增加15.17%；人均流通股21361股，较上期减少12.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208130756a43a9961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208130756a43a9961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01877","BK1583","BK1515"],"gpt_icon":0},{"id":"2589380761","title":"港股异动 | 君实生物(01877)早盘涨超3% 拓益®2项新增适应症和君适达®纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380761","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380761?lang=zh_cn&edition=full","pubTime":"2025-12-08 09:32","pubTimestamp":1765157546,"startTime":"0","endTime":"0","summary":"新版国家医保目录将于2026年1月1日起正式实施。拓益已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物；君适达为首次纳入，是新版目录中唯一用于他汀不耐受人群的国产PCSK9靶点药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","BK1161","BK0239","BK1515","BK1583","688180"],"gpt_icon":0},{"id":"2589380386","title":"80%、50种，我国医保目录成为创新药快速落地“加速器”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380386","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380386?lang=zh_cn&edition=full","pubTime":"2025-12-07 23:22","pubTimestamp":1765120920,"startTime":"0","endTime":"0","summary":"我国已建立每年一调的医保目录动态调整机制，聚焦5年内新上市药品。2025年新纳入的114种药品中，多个实现当年获批上市即进目录。2018年以来，我国1类创新药获批数量明显上升，2024年达48种，医保目录成其快速落地“加速器”，推动市场扩容。药企研发投入有稳定回报预期，将激励更多药企加大创新研发，尤其针对肿瘤、罕见病等未满足需求领域。新药从获批到纳入医保报销的时间从5年缩短至1年左右，约80%的创新药能在上市两年内进目录。医保准入成市场拓展关键，通过“腾笼换鸟”优化资源配置，推动医药行业向高质量、创新型转型。目前，2025年国家医保药品目录内药品总数达3253种，1类创新药增至50种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","LU1969619763.USD","09926","06978","01877","09688","BK1161","09995","BK1574","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2589891877","title":"君实生物：自愿披露关于偌考奇拜单抗注射液新药上市申请获得受理的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2589891877","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589891877?lang=zh_cn&edition=full","pubTime":"2025-12-07 20:37","pubTimestamp":1765111021,"startTime":"0","endTime":"0","summary":"证券日报网讯12月5日晚间，君实生物发布公告称，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，公司产品偌考奇拜单抗注射液（重组人源化抗IL-17A单克隆抗体注射液，产品代号：JS005）用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病的成人患者的新药上市申请获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584622992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0239","BK1161","BK1583","688180","01877"],"gpt_icon":0},{"id":"2589784876","title":"君实生物：拓益®新增适应症和君适达®纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589784876","media":"证券之星","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589784876?lang=zh_cn&edition=full","pubTime":"2025-12-07 15:40","pubTimestamp":1765093209,"startTime":"0","endTime":"0","summary":"君实生物公告称，公司产品特瑞普利单抗注射液2项新增适应症和昂戈瑞西单抗注射液成功纳入《国家基本医疗保险、生育保险和工伤保险药品目录》乙类范围。新版国家医保目录将于2026年1月1日起正式实施。拓益已在中国内陆获批的12项适应症全部纳入国家医保目录，是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物；君适达为首次纳入，是新版目录中唯一用于他汀不耐受人群的国产PCSK9靶点药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700002591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877","BK1515","BK0239","BK1161","BK1583"],"gpt_icon":0},{"id":"2589928878","title":"君实生物抗IL-17A单抗银屑病新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589928878","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589928878?lang=zh_cn&edition=full","pubTime":"2025-12-07 10:38","pubTimestamp":1765075080,"startTime":"0","endTime":"0","summary":"中访网数据 上海君实生物医药科技股份有限公司今日宣布，其自主研发的创新药偌考奇拜单抗注射液用于治疗中重度斑块状银屑病的新药上市申请，已获得国家药品监督管理局受理。该药物是一款重组人源化抗IL-17A单克隆抗体，通过阻断炎症信号通路发挥作用。若获批上市，偌考奇拜单抗将为该患者群体提供新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251207/31849162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK0239","688180","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2589189805","title":"君实生物(688180.SH)：偌考奇拜单抗注射液新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189805","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589189805?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:27","pubTimestamp":1764926866,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，公司产品偌考奇拜单抗注射液用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病的成人患者的新药上市申请获得受理。截至公告披露日，除本次新药上市申请外，偌考奇拜单抗用于治疗活动性强直性脊柱炎的Ⅱ期临床研究的所有参与者已完成治疗，进入安全随访期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","01877","BK1161","BK1583","688180","BK1515"],"gpt_icon":0},{"id":"2589852136","title":"上海君实生物医药科技股份有限公司发布2025年11月证券变动月报","url":"https://stock-news.laohu8.com/highlight/detail?id=2589852136","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589852136?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:55","pubTimestamp":1764892514,"startTime":"0","endTime":"0","summary":"中访网数据  上海君实生物医药科技股份有限公司于2025年12月4日向香港交易及结算所有限公司提交了截至2025年11月30日的证券变动月报表。报告显示，公司法定股本及已发行股份在本月内保持稳定，未发生变动。截至11月底，公司法定/注册股本总额为人民币1,026,689,871元。根据公司股份期权计划，截至11月底，根据H股股票期权激励计划授出的期权数目为13,210,000份，本月无变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205080055a7249b9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205080055a7249b9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","09939","BK1161","01877","BK1515","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":-0.0588},{"period":"3month","weight":-0.2887},{"period":"6month","weight":-0.0643},{"period":"1year","weight":0.7673},{"period":"ytd","weight":1.0725}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.112475},{"month":2,"riseRate":0.857143,"avgChangeRate":0.07747},{"month":3,"riseRate":0.714286,"avgChangeRate":0.049127},{"month":4,"riseRate":0.857143,"avgChangeRate":0.101581},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.100327}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}